These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30827031)

  • 1. Synthesis and biological evaluation of deuterated sofosbuvir analogs as HCV NS5B inhibitors with enhanced pharmacokinetic properties.
    Ao W; Ma X; Lin Y; Wang X; Song W; Wang Q; Zhang X; Xu H; Zhang Y
    J Labelled Comp Radiopharm; 2019 May; 62(5):215-229. PubMed ID: 30827031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir.
    Kirby BJ; Symonds WT; Kearney BP; Mathias AA
    Clin Pharmacokinet; 2015 Jul; 54(7):677-90. PubMed ID: 25822283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
    Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
    Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Complex Network of Interactions between S282 and G283 of Hepatitis C Virus Nonstructural Protein 5B and the Template Strand Affects Susceptibility to Sofosbuvir and Ribavirin.
    Kulkarni AS; Damha MJ; Schinazi RF; Mo H; Doehle B; Sagan SM; Götte M
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2018-27. PubMed ID: 26824949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B.
    Liu M; Xu Q; Guo S; Zuo R; Hong Y; Luo Y; Li Y; Gong P; Liu Y
    Bioorg Med Chem; 2018 May; 26(9):2621-2631. PubMed ID: 29681484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo.
    Zhai PB; Qing J; Li B; Zhang LQ; Ma L; Chen L
    Acta Pharmacol Sin; 2018 Nov; 39(11):1746-1752. PubMed ID: 29930277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094.
    Ehteshami M; Tao S; Ozturk T; Zhou L; Cho JH; Zhang H; Amiralaei S; Shelton JR; Lu X; Khalil A; Domaoal RA; Stanton RA; Suesserman JE; Lin B; Lee SS; Amblard F; Whitaker T; Coats SJ; Schinazi RF
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4659-69. PubMed ID: 27216050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
    Pham LV; Ramirez S; Gottwein JM; Fahnøe U; Li YP; Pedersen J; Bukh J
    Gastroenterology; 2018 Jun; 154(8):2194-2208.e12. PubMed ID: 29454794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
    Sofia MJ; Bao D; Chang W; Du J; Nagarathnam D; Rachakonda S; Reddy PG; Ross BS; Wang P; Zhang HR; Bansal S; Espiritu C; Keilman M; Lam AM; Steuer HM; Niu C; Otto MJ; Furman PA
    J Med Chem; 2010 Oct; 53(19):7202-18. PubMed ID: 20845908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.
    Tong X; Le Pogam S; Li L; Haines K; Piso K; Baronas V; Yan JM; So SS; Klumpp K; Nájera I
    J Infect Dis; 2014 Mar; 209(5):668-75. PubMed ID: 24154738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats.
    Maltais F; Jung YC; Chen M; Tanoury J; Perni RB; Mani N; Laitinen L; Huang H; Liao S; Gao H; Tsao H; Block E; Ma C; Shawgo RS; Town C; Brummel CL; Howe D; Pazhanisamy S; Raybuck S; Namchuk M; Bennani YL
    J Med Chem; 2009 Dec; 52(24):7993-8001. PubMed ID: 19894743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naïve subjects.
    Han B; Martin R; Xu S; Parvangada A; Svarovskaia ES; Mo H; Dvory-Sobol H
    Antiviral Res; 2019 Oct; 170():104574. PubMed ID: 31394118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus.
    Babusis D; Curry MP; Kirby B; Park Y; Murakami E; Wang T; Mathias A; Afdhal N; McHutchison JG; Ray AS
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29439971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells.
    Wolfisberg R; Holmbeck K; Nielsen L; Kapoor A; Rice CM; Bukh J; Scheel TKH
    J Virol; 2019 Oct; 93(19):. PubMed ID: 31292246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing the face of hepatitis C management - the design and development of sofosbuvir.
    Noell BC; Besur SV; deLemos AS
    Drug Des Devel Ther; 2015; 9():2367-74. PubMed ID: 25987834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.
    Ramirez S; Mikkelsen LS; Gottwein JM; Bukh J
    Gastroenterology; 2016 Nov; 151(5):973-985.e2. PubMed ID: 27453546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase.
    Lee S; Yoon KD; Lee M; Cho Y; Choi G; Jang H; Kim B; Jung DH; Oh JG; Kim GW; Oh JW; Jeong YJ; Kwon HJ; Bae SK; Min DH; Windisch MP; Heo TH; Lee C
    Br J Pharmacol; 2016 Jan; 173(1):191-211. PubMed ID: 26445091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
    Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
    Lemm JA; Liu M; Gentles RG; Ding M; Voss S; Pelosi LA; Wang YK; Rigat KL; Mosure KW; Bender JA; Knipe JO; Colonno R; Meanwell NA; Kadow JF; Santone KS; Roberts SB; Gao M
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3485-95. PubMed ID: 24733465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Species differences in liver accumulation and metabolism of nucleotide prodrug sofosbuvir.
    Wang T; Babusis D; Park Y; Niu C; Kim C; Zhao X; Lu B; Ma B; Muench RC; Sperger D; Ray AS; Murakami E
    Drug Metab Pharmacokinet; 2020 Jun; 35(3):334-340. PubMed ID: 32345577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.